TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21644105
Drug: Fentanyl 12.5
Normalized name: FENTANYL 12.5MCG/HR PATCH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 12.5 µg plus Morphine 0.1 mg
Study: 16491208
Drug: Fixed combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed combination of amlodipine and losartan
Study: 12794792
Drug: Intravenous doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous doxycycline
Study: 3129362
Drug: rIFN-gamma (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: rIFN-gamma (0.5 mg)
Study: 3129362
Drug: rIFN-gamma (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: rIFN-gamma (all doses)
Study: 17891897
Drug: Caffeine (CAF)
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine (CAF) 200 mg
Study: 29449791
Drug: Placebo (PLA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (PLA) 200 mg dextrose
Study: 27723543
Drug: High-dose curcumin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose curcumin extract (500mg b.i.d.)
Study: 23199378
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (autograft or lumbar disc treatment)
Study: 15531489
Drug: r-metHuLeptin (0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: r-metHuLeptin (0.05 mg/kg sc daily)
Study: 11579010
Drug: Tandospirone (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tandospirone (30 mg/day)
Study: 7968119
Drug: Amoxycillin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxycillin (500 mg three times daily for 7 days)
Study: 8141211
Drug: Erythromycin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin (500 mg four times daily for 7 days)
Study: 3475663
Drug: Placebo injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo injections of saline solution
Study: 20524068
Drug: MedCoat coated
Approvals — FDA: no, EMA: no, PMDA: no
Description: MedCoat coated divided non-flavoured placebo tablets
Study: 3822503
Drug: Low osmolar
Normalized name: Watersoluble, nephrotropic, low osmolar X-ray contrast media
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low osmolar (LO) compound
Study: 3822503
Drug: High osmolar
Normalized name: Watersoluble, nephrotropic, high osmolar X-ray contrast media
Approvals — FDA: no, EMA: no, PMDA: no
Description: High osmolar (HO) compound
Study: 17563741
Drug: Consolidation chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Consolidation chemotherapy
Study: 31586838
Drug: Repeated ketamine-assisted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated ketamine-assisted ECT (group RK), ketamine at the dose of 0.3 mg/kg for each ECT treatment
Study: 17011666
Drug: Intravenous progesterone
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous progesterone
Study: 9740462
Drug: 50 mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg/m2 methotrexate alone
Study: 27564555
Drug: Ramosetron 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramosetron 0.3 mg (TT genotype patients)
Study: 27564555
Drug: Ramosetron 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramosetron 0.3 mg (non-TT genotype patients)
Study: 27564555
Drug: Palonosetron 0.075
Normalized name: palonosetron 0.075 MG in 1.5 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palonosetron 0.075 mg (TT genotype patients)
Study: 25286965
Drug: 1% lidocaine
Normalized name: Icy Hot Max 4%-1% Lidocaine Pain Relief Dry Topical Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% lidocaine mixed with dexamethasone 2.5 mg
Study: 11426093
Drug: 5g intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5g intravenous bolus of MgSO4
Study: 9231547
Drug: Fixed-dose low
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fixed-dose low molecular weight heparin (LMWH) (Group II), 3500 units subcutaneous twice daily for a period of 5 days
Study: 2141109
Drug: L-carnitine (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-carnitine (3 g orally daily)
Study: 25777347
Drug: Chemotherapy (cisplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (cisplatin and vinorelbine) without disulfiram
Study: 24884848
Drug: Immediate loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate loading of a single mandibular midline implant with an overdenture
Study: 24884848
Drug: Delayed loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed loading of a single mandibular midline implant with an overdenture
Study: 16086839
Drug: Topical diclofenac
Normalized name: diclofenac Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical diclofenac solution (Pennsaid)
Study: 26506138
Drug: Vehicle control
Normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle control solution
Study: 7624902
Drug: Oral hydrochlorothiazide
Normalized name: hydrochlorothiazide Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral hydrochlorothiazide
Study: 6519165
Drug: Intravenous furosemide
Normalized name: Furosemide
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous furosemide
Study: 6667629
Drug: Aqueous beclomethasone
Normalized name: Pen-Aqueous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aqueous beclomethasone dipropionate nasal spray (100 micrograms into each nostril twice daily for 14 days)
Study: 6667629
Drug: Conventional pressurized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional pressurized spray
Study: 29110681
Drug: Add-on treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Add-on treatment with mianserin
Study: 29110681
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of mianserin and IRT
Study: 22097195
Drug: CM comprehensive
Normalized name: Easy Care First Aid Kit - Comprehensive KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: CM comprehensive regimen (intravenous dripping of Chinese herbal preparation, oral administration of Chinese herbal decoction, and point application)
Study: 22097195
Drug: Single-agent maintenance
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-agent maintenance chemotherapy (control)
Study: 26620049
Drug: Vildagliptin 50
Normalized name: vildagliptin 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vildagliptin 50 mg bid
Study: 19705345
Drug: Gliclazide up
Normalized name: gliclazide
DrugBank: Gliclazide (DB01120)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gliclazide up to 320 mg/day
Study: 16622596
Drug: PEG‐IFN‐alpha treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG‐IFN‐alpha treatment (6 microg/kg once a week for 8 weeks, then 3 microg/kg/week)
Study: 30206088
Drug: apixaban 2.5
Normalized name: apixaban 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: apixaban 2.5 mg twice daily
Study: 22852870
Drug: Diclofenac SR
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac SR 75 mg BID plus omeprazole 20 mg daily
Study: 9527752
Drug: Bromazepam (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromazepam (3 mg)
Study: 28935219
Drug: Medical abortion
Normalized name: ABSORPTION BASE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical abortion pills dispensed by trained pharmacy workers in Makwanpur district (GROUP 2)
Study: 28935219
Drug: Medical abortion
Normalized name: ABSORPTION BASE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical abortion pills dispensed by pharmacy workers in Chitwan district (GROUP 1)
Study: 28935219
Drug: Medical abortion
Normalized name: ABSORPTION BASE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical abortion pills dispensed by trained pharmacy workers in both groups
Study: 18807578
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation of omeprazole (20 mg)
Study: 25591469
Drug: Finerenone 1.25-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Finerenone 1.25-20 mg once daily
Study: 20944049
Drug: Postdated delayed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postdated delayed prescriptions
Study: 20944049
Drug: Usual delayed
Normalized name: HYDROGEN PEROXIDE 5 mg in 100 mL TOPICAL LIQUID [USUALKLENZ DISINFECTANTSPRAY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual delayed prescriptions
Study: 17974490
Drug: Nabilone (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nabilone (0.5 mg PO at bedtime to 1 mg BID over 4 weeks)
Study: 11978292
Drug: Methotrexate (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methotrexate (50 mg/m²) followed by misoprostol (800 micrograms vaginally)
Study: 11978292
Drug: Mifepristone (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone (600 mg) followed by misoprostol (400 micrograms orally)
Study: 8526180
Drug: Sublingual immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual immunotherapy with grass allergen extracts
Study: 786689
Drug: Propranolol (640
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (640 mg/day)
Study: 26811130
Drug: Pea fiber
Normalized name: Pea fiber
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pea fiber (PF; 15 g/d)
Study: 21297005
Drug: Medial collagen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medial collagen meniscus implant (MCMI)
Study: 21434398
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of RF EMF exposure and monotonous activity
Study: 11171650
Drug: Selective attenuation
Normalized name: varicella, live attenuated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective attenuation of gonadotropin‐releasing hormone feedforward signal intensity
Study: 11171650
Drug: Selective augmentation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective augmentation of gonadotropin‐releasing hormone feedforward signal intensity
Study: 9628521
Drug: 3.75 mg
Normalized name: zopiclone 3.75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.75 mg leuprorelin acetate depot per month i.m. + 20 mg ethinyloestradiol + 0.15 mg desogestrel orally for 3 weeks (group A)
Study: 9628521
Drug: 3.75 mg
Normalized name: zopiclone 3.75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.75 mg leuprorelin acetate depot per month i.m. + placebo (group P)
Study: 18422741
Drug: Alcohol consumption
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alcohol consumption <25 g/week
Study: 18422741
Drug: Alcohol consumption
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alcohol consumption 25-175 g/week
Study: 12930169
Drug: L-carnitine L-tartrate
Normalized name: L-carnitine (free form) (as L-carnitine L-tartrate)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-carnitine L-tartrate (2 g per day)
Study: 9110123
Drug: HMG-CoA reductase
Normalized name: HMG-CoA reductase
Approvals — FDA: no, EMA: no, PMDA: no
Description: HMG-CoA reductase inhibitors (fluvastatin, lovastatin, pravastatin, simvastatin)
Study: 9110123
Drug: Simvastatin 17.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 17.3 mg/day or 20 mg/day
Study: 28837593
Drug: Paliperidone palmitate
Normalized name: Paliperidone Palmitate
DrugBank: Paliperidone (DB01267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paliperidone palmitate once-monthly
Study: 15162916
Drug: Cardixin (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardixin (0.25 mg)
Study: 861135
Drug: Lanoxin (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lanoxin (0.25 mg)
Study: 11641292
Drug: Pet ownership
Normalized name: Pet Pectillin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pet ownership with lisinopril (20 mg/d)
Study: 11641292
Drug: Lisinopril (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril (20 mg/d) only
Study: 2692407
Drug: 3‐day treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3‐day treatment of daily 2‐h infusions of 0.5 mg/kg in 250 ml of saline (group A)
Study: 10492856
Drug: Maintenance ECT
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance ECT combined with neuroleptic medication (Phase III study)
Study: 8567331
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of hyperfractional radiotherapy with bronchial arterial infusion of anticancer drugs (Group 1, 30 cases)
Study: 7043008
Drug: Cimetidine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (300 mg four times daily for seven days)
Study: 7991070
Drug: Thyrotropin-releasing hormone
Normalized name: thyrotropin-releasing hormone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thyrotropin-releasing hormone (TRH, 500 micrograms)
Study: 7991070
Drug: GH-releasing hormone
Normalized name: thyrotropin-releasing hormone
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH-releasing hormone (GHRH, 100 micrograms)
Study: 31641887
Drug: Voglibose (0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Voglibose (0.6 mg/day)
Study: 28779371
Drug: No drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: No drugs (control)
Study: 17400624
Drug: Trust in
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Trust in pharmaceutical industry and doctors
Study: 12034600
Drug: 80 mL
Normalized name: urinary bag 480 mL MISCELL EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mL of the same contrast agent injected at a 4 mL/sec flow rate
Study: 30776899
Drug: Prebiotic inulin‐type
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prebiotic inulin‐type fructans (6 g/day)
Study: 30776899
Drug: Prebiotic inulin‐type
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prebiotic inulin‐type fructans during antibiotic treatment
Study: 21948500
Drug: Negative pressure
Normalized name: DRESSING,NEGATIVE PRESSURE WOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Negative pressure wound therapy (NPWT) during HBOT
Study: 19807887
Drug: 0.1 ml
Normalized name: ethanol 0.1 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 ml x kg(‐1) of 1% lidocaine with epinephrine 0.5 microg x kg(‐1)
Study: 16780671
Drug: Donepezil 5
Normalized name: donepezil 5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donepezil 5 mg/d
Study: 2888651
Drug: Adenosine (1/3,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adenosine (1/3, 2/3, and full maximum tolerable dose)
Study: 2888651
Drug: Metoprolol (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (10 mg to males, 8 mg to females)
Study: 31539289
Drug: Thigh administration
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thigh administration
Study: 26689403
Drug: Various metabolic
Normalized name: various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various metabolic treatment strategies
Study: 19742382
Drug: No choice
Approvals — FDA: no, EMA: no, PMDA: no
Description: No choice group (participants were assigned to their preferred treatment but believed they couldn't choose)
Study: 19742382
Drug: Wait-list control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wait-list control group (participants received no treatment until the end of the study)
Study: 10439770
Drug: Ramosetron 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramosetron 0.3 mg
Study: 12904147
Drug: Management strategies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Management strategies for anticoagulant-related bleeding
Study: 15876307
Drug: Allergen inhalation
Normalized name: catfish allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allergen inhalation
Study: 27251666
Drug: Restrictive blood
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Restrictive blood transfusion strategy (Hb levels ≥9.7 g/dL)
Study: 21654270
Drug: 40 mg/d
Normalized name: cabozantinib s-malate 140 mg/day (80 mg x 1-20 mg x 3/day) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg/d febuxostat
Study: 21654270
Drug: 60 mg/d
Normalized name: cabozantinib s-malate 60 mg/day (20 mg x 3/day) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg/d febuxostat
Study: 11280362
Drug: Self-tapping implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-tapping implants
Study: 11280362
Drug: ICE implants
Normalized name: Camphor Ice Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICE implants
Study: 11280362
Drug: Both self-tapping
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both self-tapping and ICE implants
Study: 16754218
Drug: No cryo-preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: No cryo-preparation (standard local anaesthetic injection)
Study: 31494254
Drug: Probiotic Vivomixx®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic Vivomixx® (2 sachets twice daily for 2 months)
Study: 25415784
Drug: Caudal epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caudal epidural injections
Study: 25415784
Drug: Lumbar interlaminar
Normalized name: camphor
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lumbar interlaminar epidural injections with local anesthetic only
Study: 25415784
Drug: Caudal epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caudal epidural injections with local anesthetic and steroid
Study: 22622911
Drug: Caudal epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caudal epidural injections with local anesthetic only
Study: 25415784
Drug: Lumbar interlaminar
Normalized name: camphor
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lumbar interlaminar epidural injections with local anesthetic and steroid
Study: 22721899
Drug: Vi capsular
Normalized name: typhoid vaccine VI capsular polysaccharide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vi capsular polysaccharide (ViCPS) vaccine
Study: 18325758
Drug: Testosterone patch
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone patch 30 cm2 (0.5mg/cm2)
Study: 18325758
Drug: Testosterone patch
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone patch 45 cm2 (0.5mg/cm2)
Study: 18325758
Drug: Testosterone patch
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone patch 60 cm2 (0.5mg/cm2)
Study: 7684118
Drug: Isoprinosine (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoprinosine (3 g/day)
Study: 25612299
Drug: Ponesimod 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ponesimod 2.5 mg b.i.d.
Study: 25612299
Drug: Ponesimod 5
Normalized name: ponesimod 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ponesimod 5 mg b.i.d.
Study: 25612299
Drug: Ponesimod 10
Normalized name: ponesimod 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ponesimod 10 mg q.d.
Study: 25612299
Drug: Ponesimod 20
Normalized name: ponesimod 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ponesimod 20 mg q.d.
Study: 25612299
Drug: Ponesimod 20
Normalized name: ponesimod 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ponesimod 20 mg single dose after washout period
Study: 25612299
Drug: Ponesimod 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ponesimod 2.5 mg b.i.d. and 5 mg b.i.d. morning doses
Study: 16768642
Drug: OROS methylphenidate
Approvals — FDA: no, EMA: no, PMDA: no
Description: OROS methylphenidate (MPH) 18-72 mg/day
Study: 9266276
Drug: ABT-299 0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-299 0.8 mg
Study: 9266276
Drug: ABT-299 2
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-299 2 mg
Study: 3822616
Drug: griseofulvin (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: griseofulvin (15 mg/kg/day)
Study: 3822616
Drug: ketoconazole (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: ketoconazole (5 mg/kg/day)
Study: 17419956
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (sham treatment)
Study: 22503494
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of 1000 mg of paracetamol
Study: 16094267
Drug: Dilute betadine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dilute betadine solution irrigation (3.5% betadine) before wound closure
Study: 7518815
Drug: Combined external
Normalized name: CATHETER,EXTERNAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined external irradiation and chemotherapy (bleomycin or peplomycin)
Study: 2923425
Drug: Regulated group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regulated group (n = 41) received hourly aliquots of oral fluid as determined by twice daily ward rounds.
Study: 29698720
Drug: Lidocaine dripped
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine dripped onto the skin prior to injection (1-2 ml)
Study: 29698720
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (1% subcutaneous lidocaine injection without prior skin application)
Study: 29698720
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group for peripherally inserted central catheters (1% subcutaneous lidocaine injection without prior skin application)
Study: 25463092
Drug: Ginkgo biloba
Normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginkgo biloba treatment for 2 months
Study: 11980742
Drug: Conscious sedation
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conscious sedation (2 mg midazolam and 25 microg fentanyl) i.v. 5 min before cervical dilatation
Study: 8828420
Drug: Laparoscopic local
Normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laparoscopic local methotrexate injection
Study: 1592955
Drug: CMT plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: CMT plus AST (Adjunctive Ally Support Training)
Study: 30678333
Drug: Caffeine supplementation
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine supplementation (6 mg·kg−1)